Cardiovascular (CV) outcomes were improved with finerenone therapy among patients with type 2 diabetes (T2D) and chronic kidney disease (CKD), according to a study published in The New England Journal of Medicine.

Researchers conducted a phase 3 clinical trial, FIGARO-DKD (ClinicalTrials.gov Identifier: NCT02545049), of patients (N=7352) with T2D and CKD in 48 countries between 2015 and 2019. Eligible participants for the study had CKD stage 1 or 2 with severely elevated albuminuria or CKD stage 2-4 with moderately elevated albuminuria. During a run-in period, patients were adjusted upward to the maximum dose of an angiotensin-converting-enzyme inhibitor or receptor blocker. Patients with no unacceptable side effects were randomly assigned 1:1 to receive 10 or 20 mg oral finerenone, a selective nonsteroidal mineralocorticoid receptor antagonist, or placebo daily. The 10 mg dose was given to patients with an estimated glomerular filtration rate (eGFR) of 25 to less than 60 ml/min/1.73 m2. The 20 mg dose was given to patients with an estimated eGFR of at least 60 ml/min/1.73 m2. From month 1, patients on the low dose were adjusted to the high dose. CV and renal outcomes were assessed through a median follow-up of 3.4 years.

The patient population comprised 69.4% men; participants had a mean age of 64.1±9.8 years; 71.8% were White; glycated hemoglobin was 7.7%±1.4%; eGFR was 67.8±21.7 ml/min/1.73 m2;and 45.3% had a history of cardiovascular disease.


Continue Reading

The primary composite outcome of death from CV causes, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure (HF) occurred among fewer finerenone recipients (12.4% vs 14.2%; hazard ratio [HR], 0.87; 95% CI, 0.76-0.98; P =.03).

Stratified by specific events in the primary outcome, only HF hospitalization was significantly lower among the finerenone cohort (HR, 0.71; 95% CI, 0.56-0.90).

The composite kidney outcome of kidney failure, sustained eGFR decrease of greater than or equal to 57%, or death from renal causes occurred among fewer finerenone recipients (2.9% vs 3.8%; HR, 0.77; 95% CI, 0.60-0.99).

Stratified by specific renal events, end-stage kidney disease occurred among fewer finerenone recipients (0.9% vs 1.3%; HR, 0.64; 95% CI, 0.41-0.995). The urinary albumin-to-creatinine ratio was more effectively reduced in the intervention cohort (ratio of the least-squares mean change from baseline, 0.68; 95% CI, 0.65-0.70).

Serious adverse events were reported by 31.4% of the finerenone and 33.2% of the placebo cohorts. Events led to permanent discontinuation (1.2% vs 0.4%) and hospitalization (0.6% vs 0.1%) among more of the finerenone group.

Finerenone was associated with a 0.16 mmol/l increase in serum potassium at month 1 and remained stable during the study and decreased systolic blood pressure by 3.5 mm Hg at month 4 and 2.6 mm Hg at month 24. Glycated hemoglobin and body weight were similar among groups.

This study was disrupted by the COVID-19 pandemic, in which 10 patients were lost to follow-up and 85 were excluded due to Good Clinical Practice violations.

“In the FIGARO-DKD trial, finerenone therapy improved [CV] outcomes, as compared with placebo, in patients with [T2D] who had stage 2 to 4 CKD with moderately elevated albuminuria or stage 1 or 2 CKD with severely elevated albuminuria,” the study authors noted.

Disclosure: Multiple authors declared affiliations with industry. Please refer to the original article for a full list of disclosures.

Reference

Pitt B, Filippatos G, Agarwal R, et al. Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N Engl J Med. 2021;385(24):2252-2263. doi:10.1056/NEJMoa2110956